Angivent MR

 

Angivent MR

Tablet

Generics:Trimetazidine Dihydrochloride 35mg

Square Pharmaceuticals Limited

Price/76.80Tk.

Generic

Trimetazidine Dihydrochloride

Indications

Adults should use Trimetazidine Dihydrochloride as an add-on medication for the symptomatic treatment of stable angina pectoris who are not responding to or are intolerant to first-line antianginal treatments.

Pharmacology

The first 3-ketoacyl CoA thiolase inhibitor (KAT), Trimetazidine Dihydrochloride is a metabolic anti-ischemic drug with established advantages for all cardiac patients. Trimetazidine Dihydrochloride inhibits the fatty acid route and transfers oxygen to the glucose pathway by inhibiting 3-ketoacyl CoA thiolase enzyme. Because the glucose pathway creates energy more efficiently, the same amount of oxygen produces more energy, causing the heart to beat faster. Furthermore, aerobic glucose oxidation reduces the development of lactic acid, preventing angina pectoris.

Dosage & Administration

The recommended dose of Trimetazidine is 35 mg twice daily or 20 mg tablet thrice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.

 

Interaction

So yet, no medication interactions have been observed. Beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic medicines, and digitalis preparation have all been documented to have no interactions.

Contraindications

Patients who are hypersensitive to the active ingredient or any of the excipients should avoid using trimetazidine. It's also not recommended for people who have Parkinson's disease, parkinsonian symptoms, tremors, restless legs syndrome, or significant renal impairment.

Side Effects

Trimetazidine is a drug that is both safe and well tolerated. Dizziness, headache, stomach discomfort, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria, and asthenia are all common adverse effects of Trimetazidine.

Pregnancy & Lactation

There is no information about Trimetazidine's use in pregnant women. In terms of reproductive toxicity, animal studies show no direct or indirect adverse consequences. It is advised to avoid using Trimetazidine during pregnancy as a preventative measure. Trimetazidine is not known to be excreted in human milk. A risk to neonates and infants cannot be ruled out. Breast-feeding mothers should avoid taking trimetazidine.

Precautions & Warnings

Trimetazidine is neither a cure for angina episodes, nor is it a first-line treatment for angina pectoris. It also isn't used to treat myocardial infarction.

Therapeutic Class

Other Anti-anginal & Anti-ischaemic drugs

Storage Conditions

Keep in a dry place away from light and heat. Keep out of the reach of children.

Pharmaceutical Name

Square Pharmaceuticals Ltd.